Managing cutaneous reactions to imatinib therapy.
Rule
Simon A J
SA
O'Brien
Stephen G
SG
Crossman
Lucy C
LC
D000328:Adult; D000368:Aged; D001549:Benzamides; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D005076:Exanthema / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000009:adverse effects*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000628:therapy; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy* / Q000209:etiology
D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011239:Prednisolone